Dimerix Ltd DXB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.31
- Day Range
- A$0.31–0.34
- 52-Week Range
- A$0.05–0.37
- Bid/Ask
- A$0.34 / A$0.33
- Market Cap
- A$184.12 Mil
- Volume/Avg
- 11.3 Mil / 4.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 837.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 9
- Website
- https://www.dimerix.com
Valuation
|
Metric
|
DXB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 75.70 |
Price/Sales | 837.91 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DXB
|
|---|---|
Quick Ratio | 4.84 |
Current Ratio | 4.84 |
Interest Coverage | — |
Quick Ratio
DXB
Profitability
|
Metric
|
DXB
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
DXB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wglghhdnh | Zjq | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qclpbmjbq | Qsvkp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xgzpjyjcx | Ysqfr | $99.5 Bil | |
MRNA
| Moderna Inc | Hjrgblgpz | Zvsgn | $38.8 Bil | |
ARGX
| argenx SE ADR | Bqhzqwby | Hymz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kszqnjxt | Whsl | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mkdtgytt | Pxwcj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zdvbvyb | Hbzcmfm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Myqtttgfq | Zpsjq | $12.5 Bil | |
INCY
| Incyte Corp | Wfqbslfp | Zmrqy | $11.6 Bil |